Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Recipharm Forms New Collaboration with Isofol Medical

Published: Tuesday, August 26, 2014
Last Updated: Tuesday, August 26, 2014
Bookmark and Share
Collaboration to exclusively manufacture Modufolin® and invests SEK 8 million in the company.

Recipharm and Isofol Medical AB have announced the formation of a collaboration to strengthen the development program of Isofol’s lead drug candidate Modufolin®.

At the same time, Recipharm Venture Fund, the life science sector investor with a strategic interest in pharmaceutical and biotechnology companies in need of pharmaceutical development and manufacturing support, has announced that it has invested SEK 8 million in Isofol Medical.

Isofol Medical AB is currently evaluating Modufolin® in two clinical phase I/II studies. Modufolin® is an endogenous folate-based biomodulator, developed to increase the efficacy and decrease the side effects of chemotherapeutic agents used in the treatment of solid tumors. Modufolin® is innovative and has very good sales potential and a high likelihood of reaching the market.

Carl-Johan Spak, EVP Development & Technology, Recipharm, commented: “We are very pleased to have further developed our collaborative partnership with Isofol Medical and to have now signed an agreement for future exclusive commercial manufacturing of Modufolin®, especially as this is a new, innovative drug, focused on tumor treatment and consequently has strong sales potential.”

He continued: “We look forward to putting our technical skills and capabilities to fully manufacture this exciting product whilst further assisting its development through the strategic investment.”

“Given the promising clinical data we have obtained to date we want to secure the long term manufacture and supply of Modufolin® for its future commercialization. With Recipharm’s investment of 8 MSEK in Isofol we have now raised 45 MSEK during the last 8 months. This capital and the collaboration with Recipharm not only strengthens the ongoing Phase II clinical development program but could also secure the future commercialization of Modufolin®” Anders Rabbe, Managing Director of Isofol commented.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Recipharm Secures Additional Bank Financing for Continued Growth
Company has entered a new five-year SEK 1 500 million term loan facility with three of the largest banks.
Tuesday, July 14, 2015
Recipharm Invests SEK 8 Million in Pharmanest
Investment to support the development of Pharmanest’s lead drug candidate SHACT.
Friday, July 10, 2015
Recipharm Reduces Risk and Improves Compliance with Infor
Company will also help Recipharm continue to improve compliance with the EU-GMP code of practice.
Thursday, July 09, 2015
Recipharm Appoints New Sales Director, Development Services
Amine Tahiri has joined the Development Services Sales team with effect from 1 July 2015.
Tuesday, June 30, 2015
Recipharm Acquires OnTarget Chemistry
Company extends its offering into preclinical development services.
Tuesday, June 16, 2015
Recipharm Appoints Chief Strategy Officer
Company has appointed Jean-François Hilaire to the new position of CSO.
Thursday, June 04, 2015
Recipharm Signs Partnership Agreement with Follicum
Agreement in preparation for a clinical trial of the drug candidate FOL-005.
Thursday, June 04, 2015
Recipharm Appoints New General Manager
Appointment of Giorgio Bruno as General Manager of Recipharm Italia S.p.A.
Thursday, April 30, 2015
Recipharm is Commencing Negotiations with LIDDS
Collaboration on large-scale manufacture of Liproca® Depot.
Friday, April 24, 2015
Recipharm Makes Strategic Investment in Synthonics
Recipharm has purchased $2.0 million of preferred stock in the company.
Wednesday, April 15, 2015
Recipharm and Adroit Science Form Collaboration
Company will support Recipharm’s pharmaceutical development with high quality solid state characterization services.
Thursday, March 26, 2015
Recipharm Completes Korean Serialization Project for Abbott
Validation batches planned to be shipped to Korea mid-March 2015.
Thursday, March 19, 2015
Recipharm Appoints New Position of Vice President Quality Management
Appointment of Thomas Beck with effect from 1st April 2015.
Wednesday, March 11, 2015
Recipharm Ready for Serialization and Delivers Complex Project for China
Already supplied fifty seven (57) serialized batches.
Thursday, January 29, 2015
Recipharm Acquires Flamel Technologies
Company will purchase Flamel’s development and manufacturing facility located in Pessac, France.
Thursday, November 27, 2014
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!